Ge Long Hui A P P·2025-10-09 06:36Core Viewpoint - Yuheng Pharmaceutical achieved a net profit attributable to shareholders of 134 million yuan in H1 2025, representing a year-on-year increase of 7.56% [1] Financial Performance - The company's asset-liability ratio decreased from 31.66% in the same period last year to 28.70%, indicating an ongoing optimization of the asset-liability structure and enhanced risk resistance [1] Strategic Partnerships - In H1 2025, the company signed a joint promotion agreement for Pemafibrate tablets with Xinghe Pharmaceutical and a market promotion service agreement for Mecobalamin injection with Eisai (China) [1] - Pemafibrate tablets, as a new generation of fibrate drugs, have broad market prospects, which will enrich the company's product pipeline and potentially increase revenue and profit [1] Competitive Positioning - The promotion of Pemafibrate tablets is expected to enhance the company's competitiveness in the cardiovascular field and improve its specialized academic promotion capabilities, laying the foundation for future product collaborations [1] Investment Rating - The company maintains a "Buy" rating [1]